Cutler Group LP Anavex Life Sciences Corp. Transaction History

Cutler Group LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$7.65 - $14.43 $11,475 - $21,645	1,500 New	1,500 $13,000
Q1 2022 Apr 14, 2022	SELL	$9.74 - $17.69 $7,704 - $13,992	-791 Reduced 31.64%	1,709 $21,000
Q3 2021 Oct 26, 2021	BUY	$16.82 - $25.75 $42,050 - $64,375	2,500 New	2,500 $44,000
Q2 2019 Aug 09, 2019	SELL	$2.75 - $3.7 $1,375 - $1,850	-500 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$1.68 - $3.42 $441 - $899	-263 Reduced 34.47%	500 $1,000

Q2 2018 Aug 10, 2018	SELL	$2.08 - $4.26 $3,016 - $6,177	-1,450 Reduced 65.52%	763 $1,000
Q1 2018 May 11, 2018	SELL	$2.32 - $3.44 $1,941 - $2,879	-837 Reduced 27.44%	2,213 $6,000
Q4 2017 Jan 17, 2018	SELL	$3.12 - $4.94 $45,205 - $71,575	-14,489 Reduced 82.61%	3,050 $9,000
Q3 2017 Oct 17, 2017	BUY	$3.42 - $4.87 $59,983 - $85,414	17,539	17,539 $72,000

159

31.6M

910K

1.35M

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $352M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.